Overcoming mutagenicity and ion channel activity: Optimization of selective spleen tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1929-1939

  Ellis, J Michael ^a   Altman, Michael D ^a   Bass, Alan ^a   Butcher, John W ^a   Byford, Alan J ^a   Donofrio, Anthony ^a   Galloway, Sheila ^a   Haidle, Andrew M ^a   Jewell, James ^a   Kelly, Nancy ^a   Leccese, Erica K ^a   Lee, Sandra ^a   Maddess, Matthew ^a   Miller, J Richard ^a   Moy, Lily Y ^a   Osimboni, Ekundayo ^a   Otte, Ryan D ^a   Reddy, M Vijay ^a   Spencer, Kerrie ^a   Sun, Binyuan ^a   Vincent, Stella H ^a   Ward, Gwendolyn J ^a   Woo, Grace H C ^a   Yang, Chiming ^a   Houshyar, Hani ^a   Northrup, Alan B ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; HETEROCYCLIC COMPOUND; POTASSIUM CHANNEL HERG; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AMES TEST; ARTICLE; BACTERIAL STRAIN; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; MUTAGENICITY; SALMONELLA; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MUTAGEN TESTING; SPLEEN; SYNTHESIS;

AMIDES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENICITY TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923878590     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5018169     Document Type: Article

References (35)

1. Cohen, M. H.; Williams, G.; Johnson, J. R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J.; Kim, S. K.; Wood, R.; Rothmann, M.; Chen, G.; Maung U, K.; Staten, A. M.; Pazdur, R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin. Cancer Res. 2002, 8, 935-942
2. Bonilla-Hernán, M. G.; Miranda-Carús, M. E.; Martin-Mola, E. New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors Rheumatology 2011, 50, 1542-1550
3. Müller-Ladner, U.; Pap, T.; Gay, R. E.; Neidhart, M.; Gay, S. Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis J. Clin. Pract. Rheumatol. 2005, 1, 102-110
4. Filer, A.; Parsonage, G.; Smith, E.; Osborne, C.; Thomas, A. M.; Curnow, S. J.; Rainger, G. E.; Raza, K.; Nash, G. B.; Lord, J.; Salmon, M.; Buckley, C. D. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: Site-specific versus activation-dependent survival of T cells and neutrophils Arthritis Rheum. 2006, 54, 2096-2108
5. Nimmerjahn, F.; Ravetch, J. V. Fcγ receptors as regulators of immune responses Nat. Rev. Immunol. 2008, 8, 34-47
6. Burmester, G. R.; Blanco, R.; Charles-Schoeman, C.; Wollenhaupt, J.; Zerbini, C.; Benda, B.; Gruben, D.; Wallenstein, G.; Krishnaswami, S.; Zwillich, S. H.; Koncz, T.; Soma, K.; Bradley, J.; Mebus, C. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial Lancet 2013, 381, 451-460
7. Geahlen, R. L. Getting Syk: Spleen tyrosine kinase as a therapeutic target Trends Pharmacol. Sci. 2014, 35, 414-422
8. Mocsai, A.; Ruland, J.; Tybulewicz, V. L. J. The Syk tyrosine kinase: A crucial player in diverse biological functions Nat. Rev. Immunol. 2010, 10, 387-402
9. Pine, P. R.; Chang, B.; Schoettler, N.; Banquerigo, M. L.; Wang, S.; Lau, A.; Zhao, F.; Grossbard, E. B.; Payan, D. G.; Brahn, E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor Clin. Immunol. 2007, 124, 244-257
10. Coffey, G.; DeGuzman, F.; Inagaki, M.; Pak, Y.; Delaney, S. M.; Ives, D.; Betz, A.; Jia, Z. J.; Pandey, A.; Baker, D.; Hollenbach, S. J.; Phillips, D. R.; Sinha, U. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J. Pharmacol. Exp. Ther. 2012, 340, 350-359
11. Liao, C.; Hsu, J.; Kim, Y.; Hu, D.-Q.; Xu, D.; Zhang, J.; Pashine, A.; Menke, J.; Whittard, T.; Romero, N.; Truitt, T.; Slade, M.; Lukacs, C.; Hermann, J.; Zhou, M.; Lucas, M.; Narula, S.; DeMartino, J.; Tan, S.-L. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: Implications for SYK inhibitors in autoimmune disease therapy Arthritis Res. Ther. 2013, 15, R146
12. Currie, K. S.; Kropf, J. E.; Lee, T.; Blomgren, P.; Xu, J.; Zhao, Z.; Gallion, S.; Whitney, J. A.; Maclin, D.; Lansdon, E. B.; Maciejewski, P.; Rossi, A. M.; Rong, H.; Macaluso, J.; Barbosa, J.; Di Paolo, J. A.; Mitchell, S. A. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase J. Med. Chem. 2014, 57, 3856-3873
13. Weinblatt, M. E.; Kavanaugh, A.; Genovese, M. C.; Jones, D. A.; Musser, T. K.; Grossbard, E. B.; Magilavy, D. B. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial J. Rheumatol. 2013, 40, 369-378
14. Edwards, J.; Szczepanski, L.; Szechinski, J.; Filipowicz-Sosnowska, A.; Emery, P.; Close, D.; Stevens, R.; Shaw, T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 2004, 350, 2572-81
15. For the role of VEGF inhibition in hypertension see: Pande, A.; Lombardo, J.; Spangethal, E.; Javle, M. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab Anticancer Res. 2007, 27, 3465-3470
16. Suljagic, M.; Longo, P. G.; Bennardo, S.; Perlas, E.; Leone, G.; Laurenti, L.; Efremov, D. G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling Blood 2010, 116, 4894-4905
17. Friedberg, J. W.; Sharman, J.; Sweetenham, J.; Johnston, P. B.; Vose, J. M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J. P.; Cripe, L. D.; Gregory, S. A.; Sterba, M. P.; Lowe, A. M.; Levy, R.; Shipp, M. A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010, 115, 2578-2585
18. Ulanova, M.; Duta, F.; Puttagunta, L.; Schreiber, A. D.; Befus, A. D. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis Expert Opin. Ther. Targets 2005, 9, 901-921
19. Moy, L. Y.; Jia, Y.; Caniga, M.; Lieber, G.; Gil, M.; Fernandez, X.; Sirkowski, E.; Miller, R.; Alexander, J. P.; Lee, H.-H.; Shin, J. D.; Ellis, J. M.; Chen, H.; Wilhelm, A.; Yu, H.; Vincent, S.; Chapman, R. W.; Kelly, N.; Hickey, E.; Abraham, W. M.; Northrup, A.; Miller, T.; Houshyar, H.; Crackower, M. A. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction Am. J. Respir. Cell Mol. Biol. 2013, 49, 1085-1092
20. Surry, D. S.; Buchwald, S. L. Dialkylbiaryl phosphines in Pd-catalyzed amination: A users guide Chem. Sci. 2011, 2, 27-50
21. Miyaura, N.; Yamada, K.; Suzuki, A. A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides Tetrahedron Lett. 1979, 36, 3437-3440
22. Hisamichi, H.; Naito, R.; Toyoshima, A.; Kawano, N.; Ichikawa, A.; Orita, A.; Orita, M.; Hamada, N.; Takeuchi, M.; Ohta, M.; Tsukamoto, S. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives Bioorg. Med. Chem. 2005, 13, 4936-4951
23. Villasenor, A. G.; Kendra, R.; Ho, H.; Wang, S.; Papp, E.; Shaw, D.; Barnett, J. W.; Browner, M. F.; Kuglstatter, A. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes Chem. Biol. Drug Des. 2009, 73, 466-470
24. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 2011, 24, 1345-1410
25. Data for pyridazinecarboxamide 21 from Lucas, M. C.; Bhagirath, N.; Chiao, E.; Goldstein, D. M.; Hermann, J. C.; Hsu, P.-Y.; Kirchner, S.; Kennedy-Smith, J. J.; Kuglstatter, A.; Lukacs, C.; Menke, J.; Niu, L.; Padilla, F.; Peng, Y.; Polonchuk, L.; Railkar, A.; Slade, M.; Soth, M.; Xu, D.; Yadava, P.; Yee, C.; Zhou, M.; Liao, C. Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors J. Med. Chem. 2014, 57, 2683-2691
26. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. 2000, 44, 235-249
27. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups J. Med. Chem. 2006, 49, 5029-5046
28. Wang, J.; Della Penna, K.; Wang, H.; Karczewski, J.; Connolly, T. M.; Koblan, K. S.; Bennett, P. B.; Salata, J. J. Functional and pharmacological properties of canine ERG potassium channels Am. J. Physiol. 2003, 284, 256-267
29. Higher throughput binding assay measures displacement of MK-499, a strong binder to the hERG ion channel. Priest, B. T.; Bell, I. M.; Garcia, M. L. Role of hERG potassium channel assays in drug development Channels 2008, 2, 87-93
30. Kawai, Y.; Tsukamoto, S.; Ito, J.; Akimoto, K.; Takahashi, M. A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery Chem. Pharm. Bull. (Tokyo) 2011, 59, 1110-1116
31. Liddle, J.; Atkinson, F. L.; Barker, M. D.; Carter, P. S.; Curtis, N. R.; Davis, R. P.; Douault, C.; Dickson, M. C.; Elwes, D.; Garton, N. S.; Gray, M.; Hayhow, T. G.; Hobbs, C. I.; Jones, E.; Leach, S.; Leavens, K.; Lewis, H. D.; McCleary, S.; Neu, M.; Patel, V. K.; Preston, A. G. S.; Ramirez-Molina, C.; Shipley, T. J.; Skone, P. A.; Smithers, N.; Somers, D. O.; Walker, A. L.; Watson, R. J.; Weingarten, G. G. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 6188-6194
32. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S2-R1/Step4/S2R1-Step4.pdf.
33. Adams, A.; Guss, J. M.; Denny, W. A.; Wakelin, L. P. Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons Nucleic Acids Res. 2002, 30, 719-725
34. Zang, H.; Gates, K. S. DNA binding and alkylation by the "left half" of azinomycin B Biochemistry 2000, 39, 14968-14975
35. Doxorubicin, a known intercalator, was titrated as a positve control for this assay. Structurally diverse Syk inhibitors were used as negative controls. See Northrup, A. B.; Altman, M. D.; Andresen, B. M.; Anthony, N. J.; Arrington, K. L.; Bhat, S.; Bienstock, C. E.; Black, C.; Burch, J.; Butcher, J. W.; Childers, K. K.; Cote, B.; Deschenes, D.; di Francesco, E.; Donofrio, A.; Ducharme, Y.; Dupont-Gaudet, K.; Ellis, J. M.; Fischer, C.; Fournier, J.-F.; Friesen, R.; Gauthier, J. Y.; Grimm, J. B.; Guay, D.; Guerin, D. J.; Haidle, A. M.; Jewell, J. P.; Kattar, S. D.; Li, C.; Lim, J.; Lee, S.; Liu, Y.; Machacek, M. R.; Maddess, M. L.; Miller, T. A.; OBoyle, B. M.; Otte, R. D.; Peterson, S. L.; Petrocchi, A.; Reutershan, M. H.; Romeo, E. T.; Robichaud, J. S.; Schell, A. J.; Siu, T.; Smith, G. F.; Spencer, K. B.; Taoka, B. M.; Trotter, B. W.; Yang, L.; Woo, H. C.; Zhou, H. Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, March 16-20, 2014; American Chemical Society: Washington, DC, 2014; MEDI-36.